Testing effectiveness (Phase 2)Study completedNCT02500550
What this trial is testing
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome
Kiadis Pharma 15